Hyperbaric oxygen therapy (HBOT) keeps showing up in fertility forums and a handful of IVF clinic websites as a way to thicken a stubborn uterine lining or clean up poor sperm. The honest picture is smaller and more cautious than the marketing: a few real human studies, mostly tiny, plus animal work and one well-known mechanism. This article walks through what the evidence actually says about HBOT for thin endometrium and sperm quality, where it falls apart, and how to think about it before you spend money you can't get back.
The short version of where the evidence stands
HBOT is not an FDA-cleared or guideline-recommended treatment for infertility, thin endometrium, or low sperm quality. None of the 14 conditions on the standard reimbursement list touch reproduction. What exists instead is a small body of "off-label" research: one prospective cohort in women with resistant thin lining, an older randomized study on endometrial blood flow, a retrospective case series of 15 infertile men, and a scattering of animal studies. Some of it is genuinely interesting. Almost none of it is large, blinded, or repeated.
So treat this as emerging, not established. The mechanism is plausible. The clinical proof is thin.
It helps to be clear about what "emerging" means in practice. A treatment moves from idea to standard care through a ladder: a biological rationale, then animal studies, then small uncontrolled human series, then randomized controlled trials, then large multi-center trials, then guideline endorsement and insurance coverage. HBOT for fertility sits low on that ladder, around the small-human-series and a single small randomized study rung. It has not climbed to the level where any major fertility organization recommends it, and it has not been disproven either. That middle ground is exactly where careful people get hurt, because it's easy to read a hopeful study and skip the part where the authors beg for bigger trials. The studies below are real. The certainty around them is not.
Why oxygen and pressure might matter for fertility
The whole rationale rests on a simple idea: tissues that build, repair, and function well need oxygen, and HBOT floods plasma with dissolved oxygen far beyond what hemoglobin alone carries. Under pressure (usually 2.0 to 2.4 ATA), the oxygen content of blood plasma rises enough to reach areas where small-vessel blood flow is poor.
Two fertility targets sit downstream of that.
The first is the endometrium, the uterine lining an embryo must implant into. A lining that stays thin despite estrogen often has a blood-supply problem: scarred or sparse small vessels (sometimes from prior surgery, infection, or adhesions). HBOT is thought to push two things here. One, more dissolved oxygen into poorly perfused tissue right now. Two, over repeated sessions, a signal that nudges the body to grow new capillaries (angiogenesis) and recruit repair cells. That second effect is the same one that drives HBOT's accepted use in radiation-damaged and diabetic wounds.
The second is the testis, where sperm are made. Sperm production is exquisitely sensitive to oxidative stress and heat. Some of the animal work argues HBOT can lower oxidative damage and improve the testicular environment. Other lines of thought worry the opposite, that extra oxygen could raise oxidative stress in sperm. That tension is unresolved, and it matters.
A little more detail on the angiogenesis idea, because it's the backbone of every optimistic claim about the lining. When tissue sees repeated cycles of high oxygen followed by a return to normal levels, the swing itself appears to act as a signal. Cells sense the change and ramp up growth factors such as vascular endothelial growth factor (VEGF), which drives the sprouting of new blood vessels. They also seem to recruit stem and progenitor cells that help rebuild tissue. This is not a guess pulled from fertility marketing; it's the documented basis for why HBOT helps radiation-injured and diabetic wounds heal. The leap of faith is assuming a uterine lining behaves like a chronic wound. It might. It might not. The endometrium is a hormone-driven tissue that remodels every month on its own, which is a very different environment from a leg ulcer that has stalled. So the mechanism is borrowed, and borrowed mechanisms have to be earned with direct evidence before anyone should rely on them.
On the sperm side, the timing problem deserves a flag. Sperm take roughly 70 to 90 days to develop from early cells to mature sperm in the ejaculate. Any therapy aimed at improving sperm has to be judged against that clock, because a semen analysis done a week after treatment is mostly measuring sperm that were already finished before the therapy started. Several of the existing studies don't clearly account for this, which makes their before-and-after numbers harder to trust.
| Fertility target | Proposed HBOT mechanism | What's actually proven |
|---|---|---|
| Thin endometrium | More dissolved O2 + angiogenesis improves lining thickness/receptivity | One prospective cohort + one old RCT on blood flow; no large trials |
| Endometrial blood flow | Better subendometrial perfusion, lower vessel resistance | Single small randomized study (32 women, 2006) |
| Sperm quality | Less oxidative stress, better testicular environment | Mostly animal studies; one 15-patient human case series |
| Sperm DNA fragmentation | Reduced oxidative DNA damage | Weak; improvement in ~50% of a 5-patient subgroup, not significant |
The thin endometrium evidence, study by study
This is the strongest corner of the fertility story, and it's still modest.
The 2023 frozen embryo transfer cohort
The most-cited human study is a 2023 prospective pre-post cohort from Xiangya Hospital in China, published in Reproductive Biology and Endocrinology. Researchers enrolled women with resistant thin endometrium, meaning their lining stayed under 7 mm even after standard and adjuvant therapies had failed in at least one canceled transfer cycle. These are the hardest cases, the ones who've run out of normal options.
Women voluntarily went into an HBOT group (daily sessions for at least 10 days during the proliferative phase, on top of routine lining prep) or a concurrent control group. Propensity score matching tried to make the groups comparable.
The numbers that get quoted:
- Endometrial thickness on the transformation day rose to 6.57 mm vs 5.76 mm before therapy in the HBOT group (P = 0.002), with fewer canceled cycles.
- Among women who received blastocysts, intrauterine pregnancy rate was 53.8% in the HBOT group vs 18.2% in controls (P = 0.017).
- Among women who received cleavage-stage embryos, there was no real difference (0.0% vs 6.7%, not significant).
That blastocyst pregnancy number looks impressive. Read it carefully, though. This was not a randomized, blinded trial. Patients chose their group, which invites bias. The subgroups were small, so a few pregnancies swing the percentages hard. And the lining still only reached about 6.6 mm, under the 7 mm many clinics treat as a threshold. The honest read: a promising signal in desperate cases, not proof. The authors themselves frame HBOT as "a possible choice," not a recommendation. See the study on PubMed.
It's worth sitting with why a self-selected, unblinded design is such a problem here, because the issue isn't a technicality. Women who volunteer for an extra daily treatment over ten or more days tend to differ from those who decline. They may be more motivated, more compliant with every other instruction, sometimes younger or with better embryos banked. When the group that worked harder also got the experimental therapy, you can't tell whether the therapy or the underlying difference produced the result. Randomization exists specifically to break that link, and this study didn't have it. Propensity score matching helps balance measured factors, but it can't balance the things nobody recorded. Add the fact that an unblinded patient who knows she's getting a special treatment may feel and report differently, and the placebo-and-attention effect alone could explain part of the gap. None of this means the result is fake. It means the result is fragile, and fragile results in fertility have a long record of shrinking or vanishing when someone finally runs a proper trial.
There's also a plain biology point. The lining improved by less than a millimeter on average and still didn't clear the common 7 mm bar. If you believe lining thickness is what drives implantation, a sub-millimeter bump is a small lever. If you believe blood flow and tissue quality matter more than the raw number on the ultrasound, then thickness was never the right thing to measure in the first place. Either way, the study leaves the central question open.
The 2006 endometrial blood flow study
The older anchor is a 2006 randomized study from Belgrade in 32 women with unexplained infertility, published in the Bosnian Journal of Basic Medical Sciences. Women were treated at 2.3 ATA for 70 minutes, seven days running, starting on day 5 of the cycle. Using transvaginal color Doppler, the team reported endometrial thickness around 11.0 mm at ovulation and significantly better endometrial quality in the treated cycle (P < 0.001), along with a denser, low-resistance subendometrial capillary network.
Two caveats. The study is twenty years old, small, and has not been convincingly replicated at scale. And it studied women with unexplained infertility, not specifically the resistant-thin-lining group, so you can't cleanly stack it on top of the 2023 cohort. It supports the blood-flow mechanism. It doesn't prove better babies. See the study on PubMed.
Borrowed evidence from adhesions and wounds
Beyond those two, the "evidence" for endometrium gets indirect. HBOT has reported lining benefits in women with intrauterine adhesions, and its angiogenesis effect is well documented in radiation and diabetic wound healing, both accepted indications. That borrowed plausibility is real. But borrowing a mechanism from a wound is not the same as proving it grows a fertile lining. The honest grade for thin endometrium: early human signal, low certainty.
What would actually move this up the ladder is straightforward to describe and hard to do: a randomized controlled trial that enrolls women with resistant thin endometrium, randomly assigns them to real HBOT or a credible sham (same chamber routine, minimal pressure), keeps both patients and outcome assessors blinded, and measures live birth, not just lining thickness or early pregnancy. That trial doesn't exist yet for fertility. Until it does, anyone telling you HBOT "works" for thin lining is reaching past the data. The most defensible statement today is narrower: in a small group of women who had already failed everything standard, an unblinded study saw a modest lining gain and a higher early-pregnancy rate after blastocyst transfer, and that finding is worth a real trial.
You can browse the full body of work yourself, including the adhesion and intrauterine studies, through a PubMed search on hyperbaric oxygen and thin endometrium. The list is short, which tells you most of what you need to know about how settled this is.
The sperm quality evidence, study by study
This corner is weaker and more conflicting than the endometrium side.
The 15-man case series
The headline human study is a 2021 retrospective case series of 15 infertile men who happened to receive HBOT, published in the Turkish Journal of Urology. The men split into three groups of five: high DNA fragmentation, globozoospermia (abnormally shaped sperm heads), and azoospermia (no sperm in the ejaculate).
Reported results:
- Mean sperm count in the nine measurable men rose from 8.4 to 15.7 million/mL after HBOT (azoospermic men excluded).
- Among the five azoospermic men, surgical sperm-retrieval (TESE) results improved in four of five (80%).
- DNA fragmentation improved in about 50% of the five-man fragmentation group, but this was not statistically significant (P = 0.500).
- Overall, 3 of 10 treated couples (30%) achieved healthy pregnancies through assisted reproduction.
This is interesting and basically hypothesis-generating, nothing more. Fifteen men, no control group, retrospective records, men who got HBOT "for any reason." You cannot separate the therapy's effect from natural variation, from the assisted reproduction itself, or from selection. The authors close by calling for "further studies." Take them at their word. See the study on PubMed.
A couple of specific weaknesses are worth naming. Sperm counts naturally bounce around a lot from sample to sample, sometimes doubling or halving for no reason connected to any treatment. With only nine measurable men, a count that rises from 8.4 to 15.7 million per milliliter is well within the range you might see from normal variation and regression to the mean (men picked partly because their counts were low will tend to drift back up on the next test regardless of what you do). The pregnancies, too, came through IUI, ICSI, and a rare technique called round spermatid injection, which are powerful interventions in their own right. When the assisted reproduction does the heavy lifting, attributing the babies to HBOT is a stretch. And the DNA fragmentation result, the endpoint that would matter most for many infertile men, didn't reach statistical significance in a five-person group. That's not a finding; it's noise wearing a percentage.
Animal studies and the oxidative-stress paradox
Most of the optimistic sperm data is in rodents. A 2024 rat study found HBOT preconditioning normalized scrotal temperature, sperm quality, and testicular structure after heat injury. A 2023 mouse study reported HBOT improved sperm parameters in a model by reducing oxidative stress and inflammation. Animal work is useful for mechanism, but rodent testes are not human testes, and "improved in mice" has a long history of failing to translate. Browse the sperm-quality literature on PubMed.
Here's the catch that keeps this from being a clean story. Sperm are very vulnerable to oxidative stress, and pushing extra oxygen into the body is exactly the kind of thing that can raise reactive oxygen species. Some HBOT research argues the therapy lowers net oxidative damage through adaptive antioxidant responses; other reasoning warns it could worsen sperm oxidative injury. Until human trials with sperm DNA fragmentation as a measured endpoint exist, this is genuinely unsettled.
Where HBOT lands in male-infertility comparisons
A 2023 Bayesian network meta-analysis of nonpharmacological treatments for oligoasthenospermia (low count plus poor motility) included HBOT among eight approaches across 38 randomized trials and 3,080 patients. HBOT ranked well only for improving certain reproductive hormones; warming acupuncture and electroacupuncture came out ahead on the parameters that arguably matter more, like count and motility. HBOT was not the standout. The honest grade for sperm quality: weak, conflicting, mostly preclinical. See the meta-analysis on PubMed.
How HBOT compares to standard, proven fertility options
If your lining won't thicken or your sperm parameters are poor, there's a real menu of evidence-backed steps before anyone should reach for a pressure chamber.
| Situation | Standard, better-evidenced options | Where HBOT fits |
|---|---|---|
| Thin endometrium | Higher/longer estrogen, vaginal estrogen, vasodilators (sildenafil), G-CSF infusion, PRP instillation, treating adhesions hysteroscopically | Last-resort experimental add-on after these fail |
| Poor endometrial blood flow | Low-dose aspirin, sildenafil, lifestyle and smoking cessation | Unproven alternative |
| Low sperm count/motility | Treat varicocele, correct hormones, weight loss, stop smoking, antioxidants where indicated | Not first-line; unproven |
| High sperm DNA fragmentation | Lifestyle change, antioxidants, shorter abstinence, varicocele repair, ICSI with selected sperm | Experimental, conflicting data |
| Repeated implantation failure | Full workup, ERA timing test, treating underlying disease | Investigational |
The pattern: HBOT is, at best, something to consider after the well-studied options have genuinely been exhausted, and only with a fertility specialist steering. It is never the first move.
It's also worth naming the opportunity cost, because that's the part marketing never mentions. Fertility is time-sensitive, especially for women in their late thirties and early forties. Every month spent on an unproven add-on is a month not spent on a treatment with better odds, or a month of egg quality quietly declining. A 10-to-15-session HBOT course plus scheduling can eat weeks. If those weeks would have gone to optimizing a transfer protocol, repairing a varicocele, or simply moving forward with an IVF cycle that has a known success rate, the chamber may cost more than its sticker price. The right question isn't only "could HBOT help?" but "what am I giving up by trying it first?" In most cases the answer points back to the standard menu above.
How HBOT stacks up against other adjuncts people consider is its own rabbit hole; if you're weighing alternatives broadly, our piece on the best alternatives to HBOT and what else actually works lays out the landscape without the hype.
Safety, cost, and the practical reality
HBOT is generally well tolerated when run by trained staff in a real chamber, but it isn't free of risk. The common issues are ear and sinus barotrauma from pressure changes, temporary nearsightedness that usually reverses, sinus squeeze, and claustrophobia. Rare but serious risks include oxygen toxicity seizures and lung problems. Pregnancy itself is a relative caution, which matters here because the whole point is to get pregnant; timing of any sessions relative to conception needs a doctor's input.
Then there's the money and the regulatory reality. Insurance won't cover HBOT for fertility because it isn't an approved indication, so a course is entirely out of pocket, often thousands of dollars across 10 or more sessions. The FDA has repeatedly warned consumers that HBOT is being marketed for conditions it isn't proven to treat, and urges that any HBOT be done under a physician's care in an accredited facility, not a strip-mall "wellness" chamber. For a treatment with this little fertility evidence, that warning carries weight. FDA guidance to providers on safe HBOT use.
One more distinction matters for fertility shoppers: the difference between a real medical chamber and a soft "mild HBOT" unit. The fertility studies discussed here used hospital-grade chambers pressurized to 2.0 to 2.4 ATA, the same class of device used for accepted indications. Many wellness centers and home units run "mild" HBOT at around 1.3 ATA, which delivers far less dissolved oxygen and was not what these studies tested. If someone points to the thin-endometrium cohort to justify a soft-chamber package, that's a bait-and-switch; the evidence, weak as it is, does not transfer to a different device at a different pressure. A trusted overview from a mainstream source like the Cleveland Clinic's explainer on hyperbaric oxygen therapy is a good sanity check before any clinic conversation.
For the fuller risk picture, see our deep dives on HBOT contraindications and when it's genuinely dangerous and HBOT safety during pregnancy.
Who this might reasonably be for, and who should skip it
It might be worth a careful conversation with a reproductive endocrinologist if you have resistant thin endometrium that has already failed estrogen, vasodilators, G-CSF, and PRP, and you understand you're trying an experimental add-on with low-certainty evidence. Same logic for a man with poor parameters who has exhausted the standard fixes and treats HBOT as a long shot, not a cure.
You should skip it if you're being sold HBOT as a primary fertility treatment, if a clinic guarantees results, if you haven't done a full standard workup yet, or if the chamber isn't a medical-grade, accredited setup. Those are red flags, not opportunities.
For grounding on what HBOT does and doesn't do generally, see how HBOT works, the complete science, the broader review of what the clinical research actually shows, and the standard reimbursable uses in the 14 UHMS-approved indications.
Frequently Asked Questions
Is HBOT FDA-approved for infertility or IVF?
No. There is no FDA clearance and no professional-society guideline recommending HBOT for infertility, thin endometrium, or sperm problems. None of the standard reimbursable indications involve reproduction. Any fertility use is off-label and experimental, which is also why insurance won't pay for it. See the UHMS list of approved indications.
Can HBOT really thicken a thin uterine lining?
There's a real but small signal. A 2023 prospective cohort in women with resistant thin endometrium found the lining grew modestly (to about 6.6 mm) and that blastocyst pregnancy rates were higher in the HBOT group. But it wasn't a randomized, blinded trial, the groups were self-selected, and the numbers were tiny. It's a hopeful lead in hard cases, not proof.
Does HBOT improve sperm quality or DNA fragmentation?
The human evidence is one 15-man case series with no control group, where sperm count roughly doubled in measurable men and DNA fragmentation improved in about half a five-man subgroup (not statistically significant). Most supportive data is in rats and mice. There's also a real worry that extra oxygen could increase oxidative stress in sperm. Verdict: unproven and conflicting.
Is HBOT safe to do while trying to conceive?
In an accredited facility with trained staff, HBOT is usually well tolerated, but it carries risks like ear barotrauma, temporary vision changes, and rarely oxygen toxicity. Because pregnancy is a relative caution, the timing of any sessions around conception must be managed by a physician. Don't freelance this.
Should I try HBOT before standard fertility treatments?
No. Proven options come first: optimizing estrogen, vasodilators, G-CSF or PRP for thin lining, and varicocele repair, hormone correction, and lifestyle changes for sperm. HBOT, if considered at all, is a last-resort experimental add-on after those have genuinely failed, and only with a fertility specialist guiding it.
This article is for general education only and is not medical advice. HBOT for fertility is investigational and not approved for this use; talk to a reproductive endocrinologist before making any treatment decision.